Ubs Oconnor LLC Tg Therapeutics, Inc. Call Options Transaction History

Ubs Oconnor LLC

  • $1.46 Billion
  • Q3 2024

Call Options

4 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$17.21 - $25.28 $860,500 - $1.26 Million
-50,000 Reduced 71.43%
20,000 $467,000
Q2 2024

Aug 14, 2024
SELL
$13.32 - $19.19 $666,000 - $959,500
-50,000 Reduced 41.67%
70,000 $1.25 Million
Q1 2024

May 15, 2024
BUY
$13.02 - $21.3 $911,400 - $1.49 Million
70,000 Added 140.0%
120,000 $1.83 Million
Q4 2023

Feb 14, 2024
BUY
$6.68 - $18.81 $334,000 - $940,499
50,000 New
50,000 $853,000

Others Institutions Holding TGTX

# of Institutions
339
Shares Held
88.5M
Call Options Held
2.35M
Put Options Held
1.7M
View Full List

About TG THERAPEUTICS, INC.

TGTX Quotes by TradingView
  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $5B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Ubs Oconnor LLC Portfolio

Follow Ubs Oconnor LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email